Pfizer's heart drug impresses with fast US launch

Pfizer's new heart drug nearly quadrupled Wall Street sales expectations in its first full quarter of sales in the U.S., quickly carving out a spot in a therapeutic market that features rival therapies from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.